戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 os ranged between 2.2 (pertuzumab) and 15.8 (leuprolide).
2 ed between 118.4% (sipuleucel-T) and 633.6% (leuprolide).
3 n day 4 was 56.0% with relugolix and 0% with leuprolide.
4 r delivery of peptides, including the LHRHa, leuprolide.
5 asing hormone agonist (LHRHa)-based peptide, leuprolide.
6 h a lower risk of cardiovascular events than leuprolide.
7 d peptide and blockbuster cancer therapeutic leuprolide.
8 typically following parenteral injections of leuprolide.
9 8.8% (95% CI, 84.6 to 91.8) of men receiving leuprolide.
10 in GDX mice improved by testosterone but not leuprolide.
11 patients received relugolix and 308 received leuprolide.
12 or patients taking degarelix vs those taking leuprolide (10.18 vs 8.60 events per 100 person-years; h
13 e an apnoea was greater after treatment with leuprolide (2.56 +/- 0.25 versus 4.06 +/- 0.29 Torr; P =
14 L/6J mice were injected daily with saline or leuprolide (20 mug) for 6 weeks and tested in several be
15 L/6J mice were injected daily with saline or leuprolide (20 ug) for 6 weeks and tested in several beh
16 d continued until disease progression; depot leuprolide 7.5 mg intramuscularly begun on day 5 and rep
17 en underwent administration of 18 or 36mg of leuprolide, a GnRH agonist and a larger MW peptide, via
18 nse of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, a
19 eening, women received monthly injections of leuprolide acetate (3.75 mg) for 2-3 months.
20 d the gonadotropin-releasing hormone agonist leuprolide acetate (7.5 mg intramuscularly every 4 weeks
21 nd that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing h
22  or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg).
23                         The incorporation of leuprolide acetate (LA) led to a reduced extent of burst
24                   Compositionally equivalent leuprolide acetate (LA) microspheres prepared with minor
25 n via preconditioning treatment with KGF and leuprolide acetate (Lupron), 2 clinically approved agent
26 y the gonadotropin-releasing hormone agonist leuprolide acetate (Lupron), Lupron plus estradiol repla
27                           Men received depot leuprolide acetate (Lupron, 7.5 mg intramuscularly) ever
28 stal acetate, and for 40% of those receiving leuprolide acetate (P<0.001 for each dose of ulipristal
29 h a 3-month course of NAAD that consisted of leuprolide acetate and flutamide before 3D-CRT.
30 olved after a short course of treatment with leuprolide acetate but returned after medication was dis
31 stically different between the relugolix and leuprolide acetate cohorts (hazard ratio, 0.97; 95% CI,
32    In vivo experiments on hairless rats with leuprolide acetate confirmed the potency and safety of o
33 ics of two ADT drugs Cyproterone acetate and Leuprolide acetate for individual patients.
34 ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uter
35 tal acetate were noninferior to once-monthly leuprolide acetate in controlling uterine bleeding and w
36  imaging of ISFIs in vivo and in vitro using leuprolide acetate in situ forming implant as a model dr
37 , orally once daily (360-mg loading dose) or leuprolide acetate injections every 12 weeks for 48 week
38        Only combined treatment with KGF plus leuprolide acetate normalized TEC subset numbers and thy
39 g peptide solutions of 0.2-4mM octreotide or leuprolide acetate salts in a 0.1M HEPES buffer, pH7.4,
40                                              Leuprolide acetate treatment resulted in a 3.5-fold (p <
41            Androgen deprivation therapy with leuprolide acetate was initiated, and the addition of a
42 ng hormone-releasing hormone agonist (LHRHa; leuprolide acetate) does not reduce serum androgens as e
43 et of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radi
44 e acetate, for differences (as compared with leuprolide acetate) of 1.2 percentage points (95% confid
45 .001 for each dose of ulipristal acetate vs. leuprolide acetate).
46  demonstrate that sex steroid ablation using leuprolide acetate, a luteinizing hormone-releasing horm
47 ormed to evaluate the effectiveness of depot leuprolide acetate, a synthetic gonadotropin-releasing h
48                                              Leuprolide acetate, a synthetic nonapeptide analogue of
49 h the gonadotropin-releasing hormone agonist leuprolide acetate, adding back supraphysiologic doses o
50 istal acetate, and in 89% of those receiving leuprolide acetate, for differences (as compared with le
51 Consta(R) (Risperidone) and Lupron Depot(R) (Leuprolide acetate, LA) were selected as model products.
52 y the gonadotropin-releasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leupr
53 evaluation of drug delivery technologies for leuprolide acetate, one of the most time-consuming steps
54                In response to treatment with leuprolide acetate, the threshold measured in wakefulnes
55 dotropin releasing hormone analogue (GnRHa), leuprolide acetate, to suppress OE2 for 35 days, and the
56 ted C57Bl/6J mice with the anti-gonadotropin leuprolide acetate, which suppresses both sex steroids a
57 icrosphere formulations of the hormone drug, leuprolide acetate, with similar composition to the comm
58 ompared with that achieved with placebo plus leuprolide acetate.
59 hod to rapidly assay the in vitro release of leuprolide acetate.
60 tal acetate, and 21 days for those receiving leuprolide acetate.
61 YC were offered treatment with GnRH-a (depot leuprolide acetate; a 3.75-mg monthly injection during t
62  the gonadotropin-releasing hormone agonist, leuprolide acetate; leuprolide plus estradiol; and leupr
63 .7) ng/dL (relugolix; n = 15) vs 53.0 ng/dL (leuprolide acetate; n = 8) among the subset assessed for
64 esign, each for four weeks, during continued leuprolide administration.
65  were given placebo hormone during continued leuprolide administration.
66 erity during estradiol addback compared with leuprolide alone and progesterone.
67 cer and no bone metastases to receive either leuprolide alone or leuprolide and pamidronate (60 mg in
68 ptom scores during the last 8 of 12 weeks of leuprolide alone were compared with scores during the fi
69 n symptom severity between the last month of leuprolide alone, placebo month, or second and third mon
70                          In men treated with leuprolide alone, the mean (+/-SE) bone mineral density
71 progesterone compared with the last month of leuprolide alone, the placebo month, and the second and
72 udied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasin
73                  Peptide drugs bradykinin, a leuprolide analogue, 2(PZ-128), and rapastinel are synth
74 modification of the FDA-approved cancer drug leuprolide and assembly of a library of anti-HER2 affibo
75             After 9 months of treatment with leuprolide and flutamide, androgen deprivation therapy (
76 rogen deprivation therapy (ADT) comprised of leuprolide and flutamide.
77 stases to receive either leuprolide alone or leuprolide and pamidronate (60 mg intravenously every 12
78 t any skeletal site in men treated with both leuprolide and pamidronate.
79 ost controlled-release injectable depots for leuprolide and related peptides.
80 ine 21-day cycles of docetaxel (70 mg/m(2)), leuprolide, and 3 days of testosterone.
81 six 28-day cycles of docetaxel (75 mg/m(2)), leuprolide, and 7 days of topical testosterone.
82  example, twice-a-year depot injections with leuprolide are available compared to the once-a-day inje
83 ormone antagonist, as compared with those of leuprolide are not known.
84 ng hormone-releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androg
85 ar disease who initiated either degarelix or leuprolide between December 24, 2008, and June 30, 2019.
86 leasing hormone analogues (GnRHa; nafarelin, leuprolide, buserelin, goserelin, triptorelin), laparosc
87 -releasing hormone agonists (GnRHa), such as leuprolide, can help alleviate gender dysphoria and prov
88             Thus far, the dominant means for leuprolide detection involves conventional multistep hig
89                                 In contrast, leuprolide did not significantly decrease Abeta levels a
90 al, we evaluate neoadjuvant enzalutamide and leuprolide (EL) with or without abiraterone and predniso
91                                              Leuprolide encapsulated by this approach in low-molecula
92 tropin-releasing hormone agonist leuprolide, leuprolide+estradiol addback, and leuprolide+progesteron
93 nRH antagonist degarelix or the GnRH agonist leuprolide for 12 months.
94 mechanistic signature of in vitro release of leuprolide for future comparison with corresponding in v
95 A total of 32 172 men initiated degarelix or leuprolide for prostate cancer; of them, 9490 (29.5%) ha
96 to have potential in differentiating between leuprolide formulations and establishing relationships b
97  After the initial burst release, release of leuprolide from acid-capped PLGA microspheres appeared t
98 trolled pulsatile release of the polypeptide leuprolide from microchip implants over 6 months in dogs
99                                   Release of leuprolide from the end-capped PLGA showed similar trend
100    A single water-in-oil emulsion of aqueous leuprolide/gelatin solution in PLGA 75/25 acid capped (1
101 einizing hormone-releasing hormone agonists (leuprolide, goserelin, or triptorelin) use as a time-dep
102  2.9% in the relugolix group and 6.2% in the leuprolide group (hazard ratio, 0.46; 95% CI, 0.24 to 0.
103  Fat mass increased by 11.1% +/- 1.3% in the leuprolide group and by 6.4% +/- 1.1% in the bicalutamid
104 mbar spine decreased by 2.5% +/- 0.5% in the leuprolide group and increased by 2.5 +/- 0.5 in the bic
105 golix group and 58.6 ng per deciliter in the leuprolide group.
106 common in the bicalutamide group than in the leuprolide group.
107 common in the bicalutamide group than in the leuprolide group.
108 en with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as com
109 e LHRH agonists, although CIs were wider for leuprolide (hazard ratio, 1.0994 [CI, 0.207 to 5.835]) a
110 degarelix and 11 (4.1%) patients assigned to leuprolide (hazard ratio, 1.28 [95% CI, 0.59-2.79]; P=0.
111 trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive
112 ng Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and
113                                We found that leuprolide increases hyperlocomotion, changes social pre
114 eive relugolix (120 mg orally once daily) or leuprolide (injections every 3 months) for 48 weeks.
115 ieve sustained and constant plasma levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, oct
116                   Importantly, absorption of leuprolide into low MW PLGA-COOH particles yielded ~17 w
117 y the gonadotropin-releasing hormone agonist leuprolide, leuprolide+estradiol addback, and leuprolide
118  of various incubation media on release from leuprolide-loaded PLGA microspheres to understand the in
119  low MW PLGA-COOH particles yielded ~17 wt.% leuprolide loading in the polymer (i.e., ~70% of PLGA-CO
120 ine (Tyr) amino acid residues present in the leuprolide nonapeptide, the in vitro release from liquid
121         Here, we investigated the effects of leuprolide on reproductive function, social and affectiv
122       Therapy with diethylstilbestrol (DES), leuprolide, or bilateral orchiectomy has been reported t
123  points showed superiority of relugolix over leuprolide (P<0.001).
124           The release of sorbed peptide from leuprolide-PLGA particles was evaluated both in vitro (P
125                Biopsies after treatment with leuprolide plus docetaxel showed extensive microtubule b
126 en with premenstrual syndrome who were given leuprolide plus estradiol or progesterone had a signific
127 eleasing hormone agonist leuprolide acetate, leuprolide plus estradiol, and leuprolide plus progester
128 leasing hormone agonist, leuprolide acetate; leuprolide plus estradiol; and leuprolide plus progester
129 lide acetate; leuprolide plus estradiol; and leuprolide plus progesterone.
130 lide acetate, leuprolide plus estradiol, and leuprolide plus progesterone.
131 euprolide, leuprolide+estradiol addback, and leuprolide+progesterone addback.
132 e of continuous androgen ablation induced by Leuprolide, regression of the androgen-independent tumor
133 the detection and accurate quantification of leuprolide release from formulation candidates.
134           Here, we demonstrate that assaying leuprolide release using intrinsic protein fluorescence
135 per liter) (P = 0.01) and a reduction in the leuprolide-stimulated peak serum 17 alpha-hydroxyprogest
136 easing hormone (LHRH) analogs, Nafarelin and Leuprolide, that exhibit down-regulation of their own tr
137 of GnRH agonist-induced ovarian suppression (leuprolide) then received 1 month of single-blind (parti
138 d a gonadotrophin-releasing hormone agonist, Leuprolide, to induce androgen ablation demonstrated sim
139 ivity was found in the dentate gyrus (DG) of leuprolide-treated females, but not males, consistent wi
140 demarcated the threshold was decreased after leuprolide treatment (42.1 +/- 0.6 versus 39.6 +/- 0.6 T
141 dback and progesterone addback compared with leuprolide treatment alone.
142     Ten women whose symptoms improved during leuprolide treatment were given estradiol and progestero
143 ar between patients assigned to degarelix or leuprolide was observed.
144 LGA 50/50 microspheres encapsulating ~5% w/w leuprolide were prepared by the double emulsion-solvent
145 h the gonadotropin-releasing hormone agonist leuprolide, which inhibits the hypothalamic-pituitary-go
146 terone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardi

 
Page Top